177 related articles for article (PubMed ID: 1863639)
1. Safety issues related to retroviral-mediated gene transfer in humans.
Cornetta K; Morgan RA; Anderson WF
Hum Gene Ther; 1991; 2(1):5-14. PubMed ID: 1863639
[TBL] [Abstract][Full Text] [Related]
2. Poxviral/retroviral chimeric vectors allow cytoplasmic production of transducing defective retroviral particles.
Holzer GW; Falkner FG
Methods Mol Med; 2003; 76():565-78. PubMed ID: 12526185
[No Abstract] [Full Text] [Related]
3. Recombinant retroviruses as tools for gene transfer to somatic cells.
Danos O; Heard JM
Bone Marrow Transplant; 1992; 9 Suppl 1():131-8. PubMed ID: 1324043
[No Abstract] [Full Text] [Related]
4. Mechanisms of retroviral integration and mutagenesis.
Cavazza A; Moiani A; Mavilio F
Hum Gene Ther; 2013 Feb; 24(2):119-31. PubMed ID: 23330935
[TBL] [Abstract][Full Text] [Related]
5. PCR and other test systems in human gene therapy.
Morgan RA; Anderson WF
Dev Biol Stand; 1992; 76():171-7. PubMed ID: 1478336
[TBL] [Abstract][Full Text] [Related]
6. Retroviral-mediated gene therapy--safety considerations and preclinical studies.
Tolstoshev P
Bone Marrow Transplant; 1992; 9 Suppl 1():148-50. PubMed ID: 1504657
[TBL] [Abstract][Full Text] [Related]
7. Targeting of retroviral vectors for gene therapy.
Salmons B; Günzburg WH
Hum Gene Ther; 1993 Apr; 4(2):129-41. PubMed ID: 8494923
[TBL] [Abstract][Full Text] [Related]
8. Biosafety considerations using gamma-retroviral vectors in gene therapy.
Deichmann A; Schmidt M
Curr Gene Ther; 2013 Dec; 13(6):469-77. PubMed ID: 24195605
[TBL] [Abstract][Full Text] [Related]
9. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences.
Baum C; von Kalle C; Staal FJ; Li Z; Fehse B; Schmidt M; Weerkamp F; Karlsson S; Wagemaker G; Williams DA
Mol Ther; 2004 Jan; 9(1):5-13. PubMed ID: 14741772
[TBL] [Abstract][Full Text] [Related]
10. Biosafety of onco-retroviral vectors.
VandenDriessche T; Collen D; Chuah MK
Curr Gene Ther; 2003 Dec; 3(6):501-15. PubMed ID: 14683449
[TBL] [Abstract][Full Text] [Related]
11. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis.
Modlich U; Kustikova OS; Schmidt M; Rudolph C; Meyer J; Li Z; Kamino K; von Neuhoff N; Schlegelberger B; Kuehlcke K; Bunting KD; Schmidt S; Deichmann A; von Kalle C; Fehse B; Baum C
Blood; 2005 Jun; 105(11):4235-46. PubMed ID: 15713797
[TBL] [Abstract][Full Text] [Related]
12. Retroviral vectors for gene therapy.
Maier P; von Kalle C; Laufs S
Future Microbiol; 2010 Oct; 5(10):1507-23. PubMed ID: 21073311
[TBL] [Abstract][Full Text] [Related]
13. Retroviral gene therapy: safety issues and possible solutions.
Yi Y; Hahm SH; Lee KH
Curr Gene Ther; 2005 Feb; 5(1):25-35. PubMed ID: 15638709
[TBL] [Abstract][Full Text] [Related]
14. Viral vector systems for gene therapy.
Jolly D
Cancer Gene Ther; 1994 Mar; 1(1):51-64. PubMed ID: 7621239
[No Abstract] [Full Text] [Related]
15. Genetic screens in mammalian cells by enhanced retroviral mutagens.
Liu D; Yang X; Yang D; Songyang Z
Oncogene; 2000 Dec; 19(52):5964-72. PubMed ID: 11146547
[TBL] [Abstract][Full Text] [Related]
16. Production and design of more effective avian replication-incompetent retroviral vectors.
Chen CM; Smith DM; Peters MA; Samson ME; Zitz J; Tabin CJ; Cepko CL
Dev Biol; 1999 Oct; 214(2):370-84. PubMed ID: 10525341
[TBL] [Abstract][Full Text] [Related]
17. Retrovirus-induced oncogenesis and safety of retroviral vectors.
Nair V
Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
[TBL] [Abstract][Full Text] [Related]
18. Retroviral mutagenesis of cellular oncogenes: a review with insights into the mechanisms of insertional activation.
Kung HJ; Boerkoel C; Carter TH
Curr Top Microbiol Immunol; 1991; 171():1-25. PubMed ID: 1814689
[No Abstract] [Full Text] [Related]
19. Cell line issues related to specific expression vectors: retrovirus vectors.
Morgan EM
Dev Biol Stand; 1992; 76():301-5. PubMed ID: 1478348
[TBL] [Abstract][Full Text] [Related]
20. Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives.
Baum C; Fehse B
Curr Opin Mol Ther; 2003 Oct; 5(5):458-62. PubMed ID: 14601513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
